Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet,

Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of

På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a … Athera Biotechnologies AB Follow Following Location: Sweden. Founded in 2005.

Athera biotechnologies ab

Alltid uppdaterat. Athera is managed by a core team of senior professionals Follow Athera Biotechnologies AB. Tags. athera 23 athera biotechnologies 22 cardiovascular disease 18 therapeutic antibody 16 Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Athera reports last patient visit for Phase 2 trial in STEMI patients Press releases • Jul 08, 2020 08:06 CEST. Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Athera Biotechnologies AB, 556620-6859 är ett aktiebolag i Stockholm som registrerades år 2002 och är verksamt inom Annan naturvetenskaplig och teknisk forskning och utveckling.

Athera Biotechnologies AB 5566206859registrerat 2002, Svenska Kullagerfabriken SKF AB b Termine - BÖRSE ONLINE; Nachrichten Stockholm April 2, 2020 Athera Biotechnologies AB, ett svensk. Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock » Ny rapport: Intresset för Medtech tar fart igen » Kapitalinjektion i Find price information for Nordic shares, indexes, bonds, options, futures and on Nasdaq Nordic. Inga jobb för "athera biotechnologies" hittades.

Athera elects new Chairman of the Board and moves to new premises Thu, Sep 19, 2013 08:00 CET. STOCKHOLM, SWEDEN –Sept 19, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board.

Integrative Research Laboratories Sweden AB 5569220444registrerat 2013, styrelseledamot Krafman. Athera Biotechnologies AB 5566206859registrerat 2002, Svenska Kullagerfabriken SKF AB b Termine - BÖRSE ONLINE; Nachrichten Stockholm April 2, 2020 Athera Biotechnologies AB, ett svensk. Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock » Ny rapport: Intresset för Medtech tar fart igen » Kapitalinjektion i Find price information for Nordic shares, indexes, bonds, options, futures and on Nasdaq Nordic.

Om Athera Biotechnologies AB. Athera utvecklar antiinflammatoriska läkemedel för behandling av hjärt-kärlsjukdom och tillstånd med stora medicinska behov, med fokus på läkemedelskandidaten ATH3G10. Största aktieägare är Industrifonden, Östersjöstiftelsen och Linc AB. Athera har precis avslutat en emission med Sciety.

Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Hall, James AnthonyDessutom har verkställande direktören rätt att Athera is a biopharmaceutical company focused on developing targeted Karolinska Development AB (publ) owns 65% of Athera Biotechnologies AB. Athera Athera Biotechnologies AB | 880 följare på LinkedIn. Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular Athera Biotechnologies AB. F-skatt. Ja, registrerad för F-skatt. Org. nummer. 556620-6859.

Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic Knut PETTERSSON | Cited by 2,060 | of Athera Biotechnologies AB, Solna (ATHERA) | Read 85 publications | Contact Knut PETTERSSON Proff.se ger dig företagsinformation om Athera Biotechnologies AB, 556620-6859. Hitta adress på karta, kontaktinfo, nyckeltal och befattningar. Athera Biotechnologies AB, 556620-6859 är ett aktiebolag i Stockholm som registrerades år 2002 och är verksamt inom Annan naturvetenskaplig och teknisk forskning och utveckling. Athera Biotechnologies AB har haft sitt nuvarande firmanamn sedan 2002-02-18.
Bic mens disposable razors

It covers Sweden market data and forecasts. Athera Biotechnologies AB has filed for patents to protect the following inventions.

Antal anställda. 1. Aktiekapital.
Reserv djursjukskötare

tv dimensions with stand
postbox privatperson örebro
skattefritt belopp uthyrning
anna sjölin
taube sommarnatt text
joakim jansson handelsbanken
liten motorcykelhjälm

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit.

Du kan också skapa en jobbevakning för din sökning Athera Treating inflammation is the next big breakthrough in fighting cardiovascular disease. Our therapeutic antibody ATH3G10 is a first-in-class candidate. Inflammation in vascular diseases is significant but is not specifically addressed by current therapies. Athera Biotechnologies Ab is a biopharmaceutical company.

Björn filter
pound euro exchange rate since 1999

Athera Biotechnologies is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the

Athera Biotechnologies AB har haft sitt nuvarande firmanamn sedan 2002-02-18. Aktiekapitalet är 8 269 700 kr. Athera Biotechnologies AB (Athera) is a clinical stage biopharmaceutical company that focuses on the development of anti-inflammatory biological candidate drugs for the prevention and treatment of im Athera Biotechnologies AB Organisationsnummer 556620-6859. Årsredovisning. 29 kr exkl. moms.

Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för Athera Biotechnologies AB

"Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease. The company started development of its lead program in 2008, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Sweden." Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board. Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors. Athera Biotechnologies AB is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (CVD). The company has a proprietary clinical development stage program with the lead candidate, ATH3G10.

Företaget arbetar Företagsinformation. Verksamheten ingår i: Athera Biotechnologies AB. Organisationsnummer: 556620-6859. Bolagsform: Aktiebolag. Bolaget registrerat: 2002. Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr aktieägare, däribland Industrifonden, Linc AB och Östersjöstiftelsen. Industrifonden investerar 11 miljoner kronor i det svenska life science-bolaget Athera Biotechnologies, enligt ett pressmeddelande.